XML 31 R22.htm IDEA: XBRL DOCUMENT v3.8.0.1
I. RESTATEMENT (Tables)
6 Months Ended
Mar. 31, 2017
I. Restatement Tables  
Restatements
    March 31, 2017  
Balance Sheet

  PREVIOUSLY REPORTED     ADJUSTMENT     RESTATED  
Total current assets   3,483,223     (400,039 )   3,083,184  
Other assets     5,242,616       13,754,600       18,997,216  
Total assets     8,725,839       13,354,561       22,080,400  
Total liabilities     11,802,043       13,110,357       24,912,400  
Stockholders' deficit     (3,076,204 )     244,204       (2,832,000 )

 

    September 30, 2016  
Balance Sheet

  PREVIOUSLY REPORTED     ADJUSTMENT     RESTATED  
Total current assets   5,887,646     (429,821 )   5,457,825  
Other assets     5,710,601       13,717,699       19,428,300  
Total assets     11,598,247       13,287,878       24,886,125  
Total liabilities     12,554,315       13,011,023       25,565,338  
Stockholders' deficit     (956,068 )     276,855       (679,213 )

 

    Six Months Ended March 31,  
    2017     2016  
Statement of Operations

  PREVIOUSLY REPORTED     ADJUSTMENT     RESTATED     PREVIOUSLY REPORTED     ADJUSTMENT     RESTATED  
Research and development expenses   11,080,073     (953,198 )   10,126,875     9,798,089     (953,198 )   8,844,891  
Total operating expenses     13,832,196       (953,198 )     12,878,998       12,110,486       (953,198 )     11,157,288  
Operating loss     (13,797,763 )     953,198       (12,844,565 )     (12,056,735 )     953,198       (11,103,537 )
Interest income (expense), net     45,464       (985,849 )     (940,385 )     24,463       (972,952 )     (948,489 )
Net loss     (4,872,687 )     (32,651 )     (4,905,338 )     (6,503,042 )     (19,754 )     (6,522,796 )
                                                 
Net loss per share - basic   (0.73 )           (0.74 )   (1.43 )           (1.43 )
Net loss per share - diluted   (0.78 )           (0.78 )   (1.43 )           (1.43 )

 

    Three Months Ended March 31,  
    2017     2016  
Statement of Operations

  PREVIOUSLY REPORTED     ADJUSTMENT     RESTATED     PREVIOUSLY REPORTED     ADJUSTMENT     RESTATED  
Research and development expenses   7,055,217     (476,599 )   6,578,618     4,628,582     (476,599 )   4,151,983  
Total operating expenses     8,400,331       (476,599 )     7,923,732       6,306,378       (476,599 )     5,829,779  
Operating loss     (8,383,156 )     476,599       (7,906,557 )     (6,273,603 )     476,599       (5,797,004 )
Interest income (expense), net     22,367       (493,601 )     (471,234 )     22,478       (487,274 )     (464,796 )
Net loss     (8,409,489 )     (17,002 )     (8,426,491 )     (8,844,855 )     (10,675 )     (8,855,530 )
                                                 
Net loss per share - basic and diluted   (1.15 )           (1.15 )   (1.87 )           (1.87 )

 

    Accumulated Deficit  
PREVIOUSLY REPORTED, SEPTEMBER 30, 2016   (285,667,977 )
ADJUSTMENT     276,855  
RESTATED BALANCE, SEPTEMBER 30, 2016     (285,391,122 )
         
Net loss - RESTATED     (4,905,338 )
BALANCE, MARCH 31, 2017   (290,296,460 )